| Bioactivity | SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1]. |
| Name | SARS-CoV-2-IN-14 |
| CAS | 22203-98-1 |
| Formula | C13H9Cl2NO2 |
| Molar Mass | 282.12 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295. |
SARS-CoV-2-IN-14
CAS: 22203-98-1 F: C13H9Cl2NO2 W: 282.12
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclos
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.